Bristol-Myers Squibb (NYSE:BMY) Shares Acquired by UMB Bank n.a.

UMB Bank n.a. lifted its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 178.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 205,457 shares of the biopharmaceutical company’s stock after acquiring an additional 131,595 shares during the period. UMB Bank n.a.’s holdings in Bristol-Myers Squibb were worth $11,621,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. M.E. Allison & CO. Inc. acquired a new stake in Bristol-Myers Squibb in the 4th quarter worth about $419,000. Thrive Wealth Management LLC boosted its stake in Bristol-Myers Squibb by 28.3% in the 4th quarter. Thrive Wealth Management LLC now owns 5,643 shares of the biopharmaceutical company’s stock worth $319,000 after buying an additional 1,243 shares during the last quarter. Diversify Wealth Management LLC boosted its stake in Bristol-Myers Squibb by 10.0% in the 4th quarter. Diversify Wealth Management LLC now owns 14,123 shares of the biopharmaceutical company’s stock worth $788,000 after buying an additional 1,286 shares during the last quarter. Annex Advisory Services LLC boosted its stake in Bristol-Myers Squibb by 6.0% in the 4th quarter. Annex Advisory Services LLC now owns 6,796 shares of the biopharmaceutical company’s stock worth $384,000 after buying an additional 384 shares during the last quarter. Finally, Grove Bank & Trust boosted its stake in Bristol-Myers Squibb by 14.9% in the 4th quarter. Grove Bank & Trust now owns 18,550 shares of the biopharmaceutical company’s stock worth $1,049,000 after buying an additional 2,407 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of research analyst reports. Jefferies Financial Group raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and raised their price target for the stock from $63.00 to $70.00 in a research note on Monday, December 16th. Daiwa Capital Markets upgraded Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a report on Wednesday, November 13th. Wolfe Research initiated coverage on Bristol-Myers Squibb in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Daiwa America upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 13th. Finally, Leerink Partnrs upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $56.27.

Bristol-Myers Squibb Stock Performance

Shares of BMY opened at $56.35 on Monday. The business’s 50 day moving average is $57.53 and its two-hundred day moving average is $52.00. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $61.08. The firm has a market cap of $114.30 billion, a price-to-earnings ratio of -15.70, a PEG ratio of 1.95 and a beta of 0.45. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The company had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. During the same period in the prior year, the company posted $2.00 EPS. Bristol-Myers Squibb’s quarterly revenue was up 8.4% on a year-over-year basis. Analysts forecast that Bristol-Myers Squibb will post 0.93 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.40%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date is Friday, January 3rd. Bristol-Myers Squibb’s payout ratio is -69.08%.

Insider Activity

In related news, SVP Phil M. Holzer sold 700 shares of the company’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. This represents a 5.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Samit Hirawat acquired 1,830 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were bought at an average price of $54.67 per share, with a total value of $100,046.10. Following the completion of the purchase, the executive vice president now owns 62,109 shares in the company, valued at $3,395,499.03. The trade was a 3.04 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.